Table 8.
Published studies on the use of DEX implant for other conditions
| Reference | Study design | No of eyes | Previous treatment | Primary treatment | Follow-up | Retreatment | BCVA | CMT | Complications |
|---|---|---|---|---|---|---|---|---|---|
| Furino et al81 | Retrospective | 8 PPV + ILM peeling + cataract surgery | Diclofenac sodium and betamethasone drops | DEX | 6.75±0.71 month | NR | From 20/50 to 20/23 P<0.00001 |
From 438±45 μm to 296±49 μm P<0.00001 |
No eye IOP >18 mmHg |
| Taney et al82 | Retrospective | 5 PPV with ERM peeling | Topical prednisolone 1% Topical NSAIDs Subtenon TA IVTA in 1 eye Anti-VEGF IVT in 3 eyes Anti-VEGF IVT 1 eye |
DEX | NR | 1 DEX in 3 eyes 9 DEX in 1 eye 7 DEX in 1 eye |
3 Snellen lines improvement in 3 eyes at 4–6 weeks after DEX 1 Snellen line improvement in 1 eye at 4–6 weeks after DEX No BCVA improvement in 1 eye at 4–6 weeks after DEX |
Mean CMT decrease of 106 μm (range 56–155 μm) in 4 eyes at 4–6 weeks after DEX No CMT improvement in 1 eye at 4–6 weeks after DEX |
1 eye IOP >25 mmHg Cataract in 1 out of the 2 phakic eyes |
| Merkoudis and Granstam83 | Case report | 1 PPV + ILM peeling and C2F6 tamponade + cataract surgery | IVTA Topical NSAIDs Oral CAI Anti-VEGF IVT |
1 DEX | 10 months | NR | From 20/200 to 2 months: 20/40 | Reduction of CMT 2 months after DEX | None |
| Georgalas et al84 | Case report | 1 PPV + ILM peeling cataract surgery | Topical steroids Subtenon steroids Intravitreal steroids |
1 DEX | 6 months | NR | From counting fingers to 1 week: 6/36 | From 640 μm to 1 week: 383 μm | None |
| Bonfiglio et al85 | Case report | 1 scleral buckling + cryopexy | Oral prednisolone Oral CAI Topical prednisolone Topical NSAIDs TA Subtenon |
1 DEX | 6 months | NR | From 0.70 to 6 months: 0.20 logMAR |
From 510 μm to 6 months: 290 μm | None |
Abbreviations: BCVA, best corrected visual acuity; CAI, carbonic anhydrase inhibitor; CMT, central macular thickness; DEX, dexamethasone implant; ERM, epiretinal membrane; ILM, inner limiting membrane; IOP, intraocular pressure; IVT, intravitreal; IVTA, intravitreal triamcinolone; NR, not reported; NSAIDs, nonsteroidal anti-inflammatory drugs; PPV, pars plana vitrectomy; TA, triamcinolone acetonide; VEGF, vascular endothelial growth factor.